NcXHF

CANCER SCREENING AND SURVEILLANCE
64. Wood DE, Kazerooni E, Baum SL, et al. NCCN Clinical Practice Guidelines
in Oncology (NCCN Guidelines). Lung Cancer Screening. Version
I.2015. http://www.nccn.org/professionals/physician_gls/pdf/lung_
screening.pdf. Accessed March 10, 2015.
65. Wender R, Fontham ET, Barrera E Jr, et al. American Cancer Society
lung cancer screening guidelines. CA Cancer J Clin. 2013;63:107-117.
66. American Lung Association. American Lung Association Provides
GuidanceonLungCancerScreening.http://www.lung.org/lung-disease/
lung-cancer/lung-cancer-screening-guidelines/. Accessed March 10,
2015.
67. Goulart BH, Bensink ME, Mummy DG, et al. Lung cancer screening
with low-dose computed tomography: costs, national expenditures, and
cost-effectiveness. J Natl Compr Canc Netw. 2012;10:267-275.
68. Black WC, Gareen IF, Soneji SS, et al. Cost-effectiveness of CT screening
in the National Lung Screening Trial. N Engl J Med. 2014;371:1793-
1802.
69. Croswell JM, Baker SG, Marcus PM, et al. Cumulative incidence of falsepositive
test results in lung cancer screening: a randomized trial. Ann
Intern Med. 2010;152:505-512, W176-180.
70. Ilie M, Hofman V, Long E, et al. Current challenges for detection of
circulating tumor cells and cell-free circulating nucleic acids, and their
characterization in non-small cell lung carcinoma patients. What is the
best blood substrate for personalized medicine? Ann Transl Med. 2014;
2:107.
71. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor
DNA in early- and late-stage human malignancies. Sci Transl Med.
2014;6:224ra24.
72. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease
progression, and survival in metastatic breast cancer. N Engl J Med.
2004;351:781-791.
73. Miyamoto DT, Sequist LV, Lee RJ. Circulating tumour cells-monitoring
treatment response in prostate cancer. Nat Rev Clin Oncol. 2014;11:401-
412.
74. Huang X, Gao P, Song Y, et al. Relationship between circulating tumor
cells and tumor response in colorectal cancer patients treated with chemotherapy:
a meta-analysis. BMC Cancer. 2014;14:976.
75. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor
DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368:1199-
1209.
76. Tie J KI, Wong H, et al. Massively parallel sequencing (MPS) of circulating
DNA in patients with metastatic colorectal cancer (mCRC): prognostic
signifıcance and early changes during chemotherapy (CT). J Clin
Oncol. 2013;31 (suppl; abstr 11015).
77. Hofman V, Ilie MI, Long E, et al. Detection of circulating tumor cells as
a prognostic factor in patients undergoing radical surgery for nonsmall-cell
lung carcinoma: comparison of the effıcacy of the CellSearch
Assay and the isolation by size of epithelial tumor cell method. Int J
Cancer. 2011;129:1651-1660.
78. Franken B, de Groot MR, Mastboom WJ, et al. Circulating tumor cells,
disease recurrence and survival in newly diagnosed breast cancer. Breast
Cancer Res. 2012;14:R133.
79. Sotelo MJ, Sastre J, Maestro ML, et al. Role of circulating tumor cells as
prognostic marker in resected stage III colorectal cancer. Ann Oncol.
2015;26:535-541.
80. Tie J, Kinde I, Wang Y, et al. Circulating tumor DNA (ctDNA) as a
marker of recurrence risk in stage II colon cancer (CC). J Clin Oncol.
2014;32:5s (suppl; abstr 11015).
81. Turner N G-MI, Schiavon G, et al. Tracking tumor-specifıc mutations
in circulating-free DNA to predict early relapse after treatment of primary
breast cancer. J Clin Oncol. 2014;32:5s (suppl; abstr 511).
82. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for
quantitating circulating tumor DNA with broad patient coverage. Nat
Med. 2014;20:548-554.
83. Kinde I, Bettegowda C, Wang Y, et al. Evaluation of DNA from the Papanicolaou
test to detect ovarian and endometrial cancers. Sci Transl
Med. 2013;5:167ra4.
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK 65